Dasatinib 20mg tablet is a chemotherapy drug. It is an ATP-competitive protein tyrosine kinase inhibitor. It mainly targets BCR/ABI (the Philadelphia chromosome), SRC, c-Kit, ephrin receptors, and several other tyrosine kinases. Dasatinib Tablets has half-life plasma that is active only for 3 to 4 hours, but the strong binding to BCR-ABL1 helps it to stay active for a long time, and this is the uniqueness of Dasatinib when compared to other CML treatments.
The dosage of the medicine depends upon the severity of the complications of the disease and it may vary gradually depending on the response of the body to the medicine.
Dasatinib 20mg is used to treat cases of Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL), and Philadelphia Chromosome-positive (Ph+).
It blocks the action of abnormal protein that strengthens the cancer cells to multiply.
It stops or slows down the growth of cancer cells in the body.
It treats the adults in chronic phase of Philadelphia Chromosome-positive (Ph+) who have no benefits from or couldn’t tolerate other treatments and children who have chronic Ph+ CML.
If you experience hand-foot syndrome or PPE which means rashes, swelling, redness, pain/peeling off of the skin in the hand palms and feet soles immediately after two weeks of the treatment, see your doctor, he/she might alter the dose of the medicine.
Consult your medical help immediately if the "after effects" are severe and bother your health.